US Seasonal Sales Volatility
Q3 flu season did not materialize as expected (only played out in last few days of December), unlike prior years when Q3 and Q4 delivered strong seasonal sales. This pattern may repeat and impact US revenue targets.
STAR / bear-case history
Track the concerns that keep returning.
Strides Pharma Science · risk themes across the available quarters.
Research layer active
Bear-case history
Risks carried through the record.
medium
Institutional Business Funding Uncertainty
Donor funding from organizations like Global Fund has reduced significantly as several countries cut contributions. While some countries are adding to their contributions, the gap remains very large to fill, keeping institutional revenue muted.
KOTA Allocation Delays for Control Substances
Control substances require a full year of operational track record to demonstrate manufacturing capability and earn more KOTA allocations. Management expects this cycle to complete in next 2-3 months, with FY27 expected to be 'fairly better' for this segment.
Pricing Competition in Select Products
New competitors entered couple of key products where Strides held strong market share and had good runs for last few years. Management acknowledged competition will always be present but characterized it as select molecule-specific rather than portfolio-wide.